MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
Abstract Purpose The prognostic factors for diffuse large B‐cell lymphoma (DLBCL) have been fully explored, but prognostic information for bulky mass DLBCL patients is limited. This study aimed to analyze the prognostic value of MYC protein expression and other biological parameters in bulky mass DL...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-09-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.6463 |
| _version_ | 1797361317633327104 |
|---|---|
| author | Yanjie Wang Donglin Liu Xudong Zhang Mingzhi Zhang Shenglei Li Xiaoyan Feng Meng Dong Shanshan Ma Siyu Qian Zeyuan Wang Yue Zhang Pengyuan Wang Shuhao Mei Qingjiang Chen |
| author_facet | Yanjie Wang Donglin Liu Xudong Zhang Mingzhi Zhang Shenglei Li Xiaoyan Feng Meng Dong Shanshan Ma Siyu Qian Zeyuan Wang Yue Zhang Pengyuan Wang Shuhao Mei Qingjiang Chen |
| author_sort | Yanjie Wang |
| collection | DOAJ |
| description | Abstract Purpose The prognostic factors for diffuse large B‐cell lymphoma (DLBCL) have been fully explored, but prognostic information for bulky mass DLBCL patients is limited. This study aimed to analyze the prognostic value of MYC protein expression and other biological parameters in bulky mass DLBCL patients. Methods We defined a bulky mass as a maximum tumor diameter ≥7.5 cm and studied 227 patients with de novo bulky mass DLBCL. Results In all patients with bulky mass DLBCL, the 1‐year and 3‐year OS rates were 72.7% and 57.1%, respectively, and the 1‐year and 3‐year PFS rates were 52.0% and 42.5%, respectively. The MYC overexpression group (n = 140) showed significantly worse overall survival (OS; p = 0.019) and progression‐free survival (PFS; p = 0.001) than the non‐MYC overexpression group (n = 87). Subgroup analyses demonstrated that the MYC overexpression group was associated with inferior OS and PFS in the subgroups with the International Prognostic Index score of 3–5 (OS: p = 0.011; PFS: p < 0.001), Ann Arbor stage 3–4 (OS: p = 0.014; PFS: p < 0.001) and GCB subtype (OS: p = 0.014; PFS: p = 0.010). Consolidation radiotherapy improved OS and PFS in patients with bulky mass DLBCL (OS: p = 0.008; PFS: p = 0.004) as well as in those with MYC overexpression (OS: p = 0.001; PFS: p = 0.001). The prognostic value of MYC overexpression was maintained in a multivariate model adjusted for the International Prognostic Index. Conclusion MYC overexpression is a poor predictor for bulky mass DLBCL patients. Consolidation radiotherapy for residual disease after induction therapy may improve outcomes for patients with bulky mass DLBCL. |
| first_indexed | 2024-03-08T15:52:10Z |
| format | Article |
| id | doaj.art-ebe22fde74ef450995b6d593634d26e4 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-08T15:52:10Z |
| publishDate | 2023-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-ebe22fde74ef450995b6d593634d26e42024-01-09T05:21:15ZengWileyCancer Medicine2045-76342023-09-011218185681857710.1002/cam4.6463MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patientsYanjie Wang0Donglin Liu1Xudong Zhang2Mingzhi Zhang3Shenglei Li4Xiaoyan Feng5Meng Dong6Shanshan Ma7Siyu Qian8Zeyuan Wang9Yue Zhang10Pengyuan Wang11Shuhao Mei12Qingjiang Chen13Department of Oncology, Henan Province Lymphoma Treatment Center The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Oncology, Henan Province Lymphoma Treatment Center The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Oncology, Henan Province Lymphoma Treatment Center The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Oncology, Henan Province Lymphoma Treatment Center The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Pathology The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Oncology, Henan Province Lymphoma Treatment Center The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Oncology, Henan Province Lymphoma Treatment Center The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Oncology, Henan Province Lymphoma Treatment Center The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Oncology, Henan Province Lymphoma Treatment Center The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Pathology The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Oncology, Henan Province Lymphoma Treatment Center The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaDepartment of Medical Oncology Xuchang Central Hospital Xuchang ChinaDepartment of Hematology Xuchang Central Hospital Xuchang ChinaDepartment of Oncology, Henan Province Lymphoma Treatment Center The First Affiliated Hospital of Zhengzhou University Zhengzhou ChinaAbstract Purpose The prognostic factors for diffuse large B‐cell lymphoma (DLBCL) have been fully explored, but prognostic information for bulky mass DLBCL patients is limited. This study aimed to analyze the prognostic value of MYC protein expression and other biological parameters in bulky mass DLBCL patients. Methods We defined a bulky mass as a maximum tumor diameter ≥7.5 cm and studied 227 patients with de novo bulky mass DLBCL. Results In all patients with bulky mass DLBCL, the 1‐year and 3‐year OS rates were 72.7% and 57.1%, respectively, and the 1‐year and 3‐year PFS rates were 52.0% and 42.5%, respectively. The MYC overexpression group (n = 140) showed significantly worse overall survival (OS; p = 0.019) and progression‐free survival (PFS; p = 0.001) than the non‐MYC overexpression group (n = 87). Subgroup analyses demonstrated that the MYC overexpression group was associated with inferior OS and PFS in the subgroups with the International Prognostic Index score of 3–5 (OS: p = 0.011; PFS: p < 0.001), Ann Arbor stage 3–4 (OS: p = 0.014; PFS: p < 0.001) and GCB subtype (OS: p = 0.014; PFS: p = 0.010). Consolidation radiotherapy improved OS and PFS in patients with bulky mass DLBCL (OS: p = 0.008; PFS: p = 0.004) as well as in those with MYC overexpression (OS: p = 0.001; PFS: p = 0.001). The prognostic value of MYC overexpression was maintained in a multivariate model adjusted for the International Prognostic Index. Conclusion MYC overexpression is a poor predictor for bulky mass DLBCL patients. Consolidation radiotherapy for residual disease after induction therapy may improve outcomes for patients with bulky mass DLBCL.https://doi.org/10.1002/cam4.6463diffuse large B‐cell lymphomabulky massimmunohistochemistrylymphomaMYCradiotherapy |
| spellingShingle | Yanjie Wang Donglin Liu Xudong Zhang Mingzhi Zhang Shenglei Li Xiaoyan Feng Meng Dong Shanshan Ma Siyu Qian Zeyuan Wang Yue Zhang Pengyuan Wang Shuhao Mei Qingjiang Chen MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients Cancer Medicine diffuse large B‐cell lymphoma bulky mass immunohistochemistry lymphoma MYC radiotherapy |
| title | MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients |
| title_full | MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients |
| title_fullStr | MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients |
| title_full_unstemmed | MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients |
| title_short | MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients |
| title_sort | myc overexpression but not myc bcl2 double expression predicts survival in bulky mass diffuse large b cell lymphoma patients |
| topic | diffuse large B‐cell lymphoma bulky mass immunohistochemistry lymphoma MYC radiotherapy |
| url | https://doi.org/10.1002/cam4.6463 |
| work_keys_str_mv | AT yanjiewang mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT donglinliu mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT xudongzhang mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT mingzhizhang mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT shengleili mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT xiaoyanfeng mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT mengdong mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT shanshanma mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT siyuqian mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT zeyuanwang mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT yuezhang mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT pengyuanwang mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT shuhaomei mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients AT qingjiangchen mycoverexpressionbutnotmycbcl2doubleexpressionpredictssurvivalinbulkymassdiffuselargebcelllymphomapatients |